CGEM · Insider Trading
Cullinan Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by CGEM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Jennifer Michaelson | Chief Scientific Officer | MIXED | −4,000 | −$155.36K |
| 2026-08-14 | Jennifer Michaelson | Chief Scientific Officer | MIXED | — | −$478.80K |
| 2026-07-07 | Jennifer Michaelson | Chief Scientific Officer | MIXED | −4,000 | −$125.36K |
| 2026-07-02 | Jacquelyn L Sumer | Chief Legal Officer | A | +2,470 | +$21.24K |
| 2026-07-02 | Mary Kay Fenton | Chief Financial Officer | A | +1,541 | +$13.25K |
| 2026-06-18 | Stephen W Webster | Director | A | +25,319 deriv. | — |
| 2026-06-18 | Mittie Doyle | Director | A | +21,781 deriv. | — |
| 2026-06-18 | Mary Thistle | Director | A | +25,319 deriv. | — |
| 2026-06-18 | David D. Meek | Director | A | +25,319 deriv. | — |
| 2026-06-18 | Anthony Rosenberg | Director | A | +25,319 deriv. | — |
| 2026-06-18 | Andrew R Allen | Director | A | +21,781 deriv. | — |
| 2026-05-06 | Jennifer Michaelson | Chief Scientific Officer | MIXED | −4,000 | −$99.80K |
| 2026-03-09 | Jennifer Michaelson | Chief Scientific Officer | MIXED | −4,000 | −$108.24K |
| 2026-02-26 | Jennifer Michaelson | Chief Scientific Officer | Sell | −1,780 | −$25.17K |
| 2026-02-25 | Nadim Ahmed | President and CEO | Sell | −13,515 | −$195.56K |
| 2026-02-25 | Jennifer Michaelson | Chief Scientific Officer | Sell | −5,353 | −$76.62K |
| 2026-02-25 | Jeffrey Alan Jones | Chief Medical Officer | Sell | −4,582 | −$66.30K |
| 2026-02-25 | Jacquelyn L Sumer | Chief Legal Officer | Sell | −3,601 | −$52.11K |
| 2026-02-23 | Nadim Ahmed | President and CEO | Sell | −16,381 | −$223.11K |
| 2026-02-23 | Jennifer Michaelson | Chief Scientific Officer | MIXED | −3,742 | −$130.97K |
| 2026-02-23 | Jeffrey Alan Jones | Chief Medical Officer | Sell | −4,982 | −$67.85K |
| 2026-02-23 | Jacquelyn L Sumer | Chief Legal Officer | Sell | −3,742 | −$50.97K |
| 2026-02-23 | Mary Kay Fenton | Chief Financial Officer | Sell | −4,398 | −$59.90K |
| 2026-02-19 | Corrine Savill | Chief Business Officer | A | +175,000 deriv. | — |
| 2026-02-19 | Jennifer Michaelson | Chief Scientific Officer | A | +57,500 | — |
| 2026-02-19 | Jeffrey Alan Jones | Chief Medical Officer | A | +300,000 deriv. | — |
| 2026-02-19 | Mary Kay Fenton | Chief Financial Officer | A | +68,750 | — |
| 2026-02-19 | Nadim Ahmed | President and CEO | A | +828,000 deriv. | — |
| 2026-02-19 | Jacquelyn L Sumer | Chief Legal Officer | A | +230,000 deriv. | — |
| 2026-02-13 | Jennifer Michaelson | Chief Scientific Officer | Sell | −416 | −$5.00K |
| 2026-01-23 | Jennifer Michaelson | Chief Scientific Officer | Sell | −4,000 | −$49.20K |
| 2026-01-05 | Mary Kay Fenton | Chief Financial Officer | A | +27 | +$175 |
| 2025-12-29 | Nadim Ahmed | President and CEO | Sell | −9,922 | −$99.32K |
| 2025-12-22 | Jennifer Michaelson | Chief Scientific Officer | Sell | −1,345 | −$13.46K |
| 2025-12-19 | Jacquelyn L Sumer | Chief Legal Officer | Sell | −3,480 | −$33.65K |
| 2025-12-19 | Jeffrey Alan Jones | Chief Medical Officer | Sell | −4,632 | −$44.79K |
| 2025-12-19 | Jennifer Michaelson | Chief Scientific Officer | Sell | −2,898 | −$28.02K |
| 2025-12-16 | Jennifer Michaelson | Chief Scientific Officer | Sell | −3,143 | −$38.43K |
| 2025-11-25 | Jennifer Michaelson | Chief Scientific Officer | Sell | −4,000 | −$49.20K |
| 2025-10-30 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +331,334 | +$2.78M |
| 2025-10-21 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +497,498 | +$4.21M |
| 2025-10-10 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +2,919,282 | +$19.65M |
| 2025-08-08 | Mittie Doyle | Director | A | +79,456 deriv. | — |
| 2025-08-08 | Andrew R Allen | Director | A | +79,456 deriv. | — |
| 2025-06-16 | Anne-Marie Martin | Director | A | +38,513 deriv. | — |
| 2025-06-16 | David P. Ryan | Director | A | +38,513 deriv. | — |
| 2025-06-16 | David D. Meek | Director | A | +38,513 deriv. | — |
| 2025-06-16 | Anthony Rosenberg | Director | A | +38,513 deriv. | — |
| 2025-06-16 | Stephen W Webster | Director | A | +38,513 deriv. | — |
| 2025-02-27 | Nadim Ahmed | President and CEO | Sell | −12,529 | −$106.87K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Lynx1 Capital Management LP | 10%+ Owner | 8,963,500 | $130.33M |
| Nadim Ahmed | President and CEO | 390,803 | $5.68M |
| Corrine Savill | Chief Business Officer | 240,990 | $3.50M |
| Jennifer Michaelson | Chief Scientific Officer | 166,844 | $2.43M |
| Jeffrey Alan Jones | Chief Medical Officer | 159,968 | $2.33M |
| Jacquelyn L Sumer | Chief Legal Officer | 130,559 | $1.90M |
| Mary Kay Fenton | Chief Financial Officer | 127,921 | $1.86M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CGEM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.